RFXAP

Across TCGA pan-cancer cohorts, RFXAP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RFXAP data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RFXAP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RFXAP expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where RFXAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.772	0.478	<.001	97	view →
PDAC	DFS	Quartile	All	0.978	0.490	<.001	41	view →
CCRCC	DFS	Quartile	All	0.863	1.000	.019	14	view →
HNSC	DFS	Median	II,III,IV	0.860	0.981	.009	7	view →
GBM	DFS	Quartile	All	0.482	0.240	.026	5	view →
LSCC	DFS	Median	All	0.686	0.876	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RFXAP–LUAD (DFS)

Open the LUAD breakdown →